Advertisement

Dermatologie pp 295-298 | Cite as

Experimentelle Therapie des Melanoms: Relevanz für Klinik und Praxis

  • R. Dummer
  • F. Nestle
  • M. Krasovec
  • G. Burg
Conference paper

Zusammenfassung

Dem niedergelassenen Dermatologen mag der Gedanke an experimentelle Therapieformen wie Gentherapie in der Praxis als sehr abwegig, futuristisch und wirklichkeitsfremd vorkommen. Deshalb werden viele Kollegen dieses Thema verdrängen und sich nicht weiter damit auseinandersetzen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gplOO is recognized by melanoma- derived tumor-infiltrating lymphocytes. J Exp Med 179: 1005–1009Google Scholar
  2. 2.
    Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, Plotkin S (1992) Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 339: 1429–32PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen J (1993) Naked DNA points way to vaccines. Science 259: 1691–2PubMedCrossRefGoogle Scholar
  4. 4.
    Dummer R, Boni R (1995) Wie entkommen Melanomzellen der Immunantwort? Konsequenzen fur zukunftige Therapieansatze und gegenwartige Biopsieverarbeitung. Schweiz Med Wochenschr 125: 1638–41PubMedGoogle Scholar
  5. 5.
    Dummer R, Davis-Daneshfar A, Döhring C, Döbbeling U, Burg G (1995) Strategien zur Gentherapie des Melanoms. Hautarzt 46: 305–308PubMedCrossRefGoogle Scholar
  6. 6.
    Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC, Tschopp J (1996) Melanoma Cell Expression Of Fas(Apo-l/Cd95) Ligand - Implications For Tumor Immune Escape. Science 274: 1363–1366PubMedCrossRefGoogle Scholar
  7. 7.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17PubMedGoogle Scholar
  8. 8.
    Lanzavecchia A (1993) Identifying strategies for immune intervention. Science 260: 937–944PubMedCrossRefGoogle Scholar
  9. 9.
    Mulligan RC (1993) The basic science of gene therapy. Science 260: 926–932PubMedCrossRefGoogle Scholar
  10. 10.
    Pialoux G, Excler JL, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, Kieny MP et al. (1995) A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and TAgence Nationale de Recherche sur le SIDA [published erratum appears in AIDS Res Hum Retroviruses 1995 Jul;ll(7):875]. AIDS Research 8c Human Retroviruses 11: 373–81CrossRefGoogle Scholar
  11. 11.
    Van der Brüggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643–1647PubMedCrossRefGoogle Scholar
  12. 12.
    Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt MT, Huang WM, Johnson DE, Anderson SC, Wen SF et al. (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5: 1079–1088PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • R. Dummer
  • F. Nestle
  • M. Krasovec
  • G. Burg

There are no affiliations available

Personalised recommendations